Literature DB >> 8415820

Pica in rats is analogous to emesis: an animal model in emesis research.

N Takeda1, S Hasegawa, M Morita, T Matsunaga.   

Abstract

Mitchell et al. (1976, 1977) suggested that pica, eating of nonnutritive substances such as kaolin, is an illness-response behavior in rats. In the present study, we first confirmed their suggestion and then examined the effects of antiemetics on emetic-induced pica in rats. Intraperitoneal injection of apomorphine induced dose-dependent kaolin consumption. Pretreatment with domperidone inhibited apomorphine-induced kaolin intake. Oral administration of copper sulfate and intraperitoneal injection of cisplatin also induced dose-dependent kaolin consumption. Pretreatment with ondansetron inhibited cisplatin-induced kaolin intake. These findings suggest that pica in rats was induced through 1) dopamine D2 receptors in the chemoreceptor trigger zone, and 2) the stomach, partly via 5-HT3 receptors in the visceral afferents in the stomach wall. The present findings support the conclusion that pica in rats is analogous to vomiting in other species and suggest that pica in rats is mediated by the same mechanisms as vomiting in humans. Accordingly, we extended the utility of the animal model to pharmacological research of emesis with pica as an analogue to emesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8415820     DOI: 10.1016/0091-3057(93)90126-e

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  64 in total

Review 1.  Developmental specification of metabolic circuitry.

Authors:  Amanda E Elson; Richard B Simerly
Journal:  Front Neuroendocrinol       Date:  2015-09-25       Impact factor: 8.606

2.  GDF15 Induces an Aversive Visceral Malaise State that Drives Anorexia and Weight Loss.

Authors:  Tito Borner; Hallie S Wald; Misgana Y Ghidewon; Bei Zhang; Zhidan Wu; Bart C De Jonghe; Danna Breen; Harvey J Grill
Journal:  Cell Rep       Date:  2020-04-21       Impact factor: 9.423

3.  Brain Fos expression during 48 h after cisplatin treatment: neural pathways for acute and delayed visceral sickness.

Authors:  Charles C Horn; Marc Ciucci; Arun Chaudhury
Journal:  Auton Neurosci       Date:  2006-11-07       Impact factor: 3.145

4.  A cluster of gustducin-expressing cells in the mouse stomach associated with two distinct populations of enteroendocrine cells.

Authors:  Nicole Hass; Karin Schwarzenbacher; Heinz Breer
Journal:  Histochem Cell Biol       Date:  2007-09-15       Impact factor: 4.304

Review 5.  The utility of animal models to evaluate novel anti-obesity agents.

Authors:  Steven P Vickers; Helen C Jackson; Sharon C Cheetham
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 6.  Side effects of pain and analgesia in animal experimentation.

Authors:  Paulin Jirkof
Journal:  Lab Anim (NY)       Date:  2017-03-22       Impact factor: 12.625

7.  Effects of repeated morphine on ultrasonic vocalizations in adult rats: increased 50-kHz call rate and altered subtype profile.

Authors:  Laura M Best; Leah L Zhao; Tina Scardochio; Paul B S Clarke
Journal:  Psychopharmacology (Berl)       Date:  2016-10-11       Impact factor: 4.530

8.  Liraglutide pharmacotherapy reduces body weight and improves glycaemic control in juvenile obese/hyperglycaemic male and female rats.

Authors:  Claudia G Liberini; Rinzin Lhamo; Misgana Ghidewon; Tyler Ling; Nina Juntereal; Jack Chen; Anh Cao; Lauren M Stein; Matthew R Hayes
Journal:  Diabetes Obes Metab       Date:  2018-12-21       Impact factor: 6.577

Review 9.  What is nausea? A historical analysis of changing views.

Authors:  Carey D Balaban; Bill J Yates
Journal:  Auton Neurosci       Date:  2016-07-16       Impact factor: 3.145

10.  Protease inhibitor-induced nausea and vomiting is attenuated by a peripherally acting, opioid-receptor antagonist in a rat model.

Authors:  Chun-Su Yuan; Chong-Zhi Wang; Sangeeta R Mehendale; Han H Aung; Adela Foo; Robert J Israel
Journal:  AIDS Res Ther       Date:  2009-08-21       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.